Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372

German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe Biopharma Co., Ltd, acquiring global exclusive development, manufacturing, and commercialization rights to the Chinese firm’s MTA-cooperative PRMT5 inhibitor, designated as BAY 3713372. Financial details of the deal were not disclosed. Bayer has enrolled the first patient in the Phase I dosage escalation study evaluating the drug in MTAP-deficient solid tumors.

Drug Development and Targeting
BAY 3713372, an investigational drug not yet approved anywhere in the world, is notable for its brain permeability, enabling it to target central nervous system (CNS) metastases and primary brain tumors. This unique feature positions the drug as a potential candidate for addressing unmet medical needs in brain-related malignancies.-Fineline Info & Tech